BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Moderna Announces Superiority of Bivalent Booster

  Pharma giant Moderna has shared data on the development of a new bivalent COVID-19 booster vaccine that performs better than its first booster that is currently on the market.

  April 19, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Business

  Cassava Faces Renewed Speculation Over Experimental Alzheimer’s Drug

  Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.

  April 19, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  BioXcel Launches OnkosXcel to Advance High-Potential Oncology Asset

  New Haven, Conn.-based BioXcel Therapeutics launched a wholly-owned subsidiary, OnkosXcel, to focus on oncology.

  April 19, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  INmune Bio Tackles Neuroinflammation in Phase II Alzheimer’s Trial

  INmune Bio has announced that it has dosed the first patient in its Phase II clinical trial of XPro1595 for the treatment of neuroinflammation as a cause of Alzheimer’s Disease.

  April 19, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Exploring the Therapeutic Potential of Protective Genetic Variations

  Genetic varations within the human genome is littered with breadcrumbs leading right up to new therapeutic possibilities.

  April 19, 2022

   · 

  5 min read

   · 

  Kaylei Whalen
• 

  Drug Development

  J&J Cuts 2022 Sales Projections by $1 Billion

  Following first-quarter results, Johnson & Johnson is projecting almost $1 billion less in revenue for the year than the initial guidance it gave in January.

  April 19, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Axsome and Aytu’s Positive Day with the FDA

  Axsome Therapeutics received good news regarding its NDA for AXS-05, a treatment for depression, and Aytu BioScience received Fast Track designation for its VEDS treatment.

  April 19, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Acadia’s Star CerSci Acquisition Fails First Test in Acute Pain

  Acadia Pharmaceuticals faces a major hurdle after top-line results from its study of ACP-044 for post-surgery pain failed to meet desired outcomes.

  April 19, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Drug Development

  Finch Slashes 20% of Headcount to Hone in on C.Diff, Autism

  Finch Therapeutics has slashed its headcount by 20% in order to free funds to focus its resources on its programs in recurrent C. difficile infection and autism spectrum disorder

  April 19, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Revive, Ascletis Provide Positive Updates on Potential COVID-19 Therapies

  Two investigational drugs have been taking the spotlight recently from Revive and Ascletis as they share news regarding their potential treatment against COVID-19.

  April 19, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN